Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Vicken Karageozian
AddedFeb 15, 2024
UpdatedMay 31, 2026
Vicken Karageozian

Vicken Karageozian

Co-Founder, Vitreoretinal Technologies

CrunchbaseLinkedInThe Org

Vicken Karageozian's Career

Vitreoretinal Technologies
Vitreoretinal Technologies

Irvine, CA, US

Co-Founder
Allegro Ophthalmics
Allegro Ophthalmics

San Juan Capistrano, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Vicken Karageozian's Career

Vitreoretinal Technologies
Vitreoretinal Technologies
Series A$12M61999Irvine, CA, US
Co-Founder

Leadership at Vitreoretinal Technologies

Hampar KarageozianHampar KarageozianCo-Founder
Allegro Ophthalmics
Allegro Ophthalmics
Private Equity$42.7M112011San Juan Capistrano, CA, US
Co-Founder

Leadership at Allegro Ophthalmics

Dr. Ronald M. Kurtz M.D.Dr. Ronald M. Kurtz M.D.Board Member
William LinkWilliam LinkBoard Member
Mark LivingstonMark LivingstonBoard Member
John ParkJohn ParkCo-Founder
Rebecca ColbertRebecca ColbertBoard Member
Tom BenderTom BenderBoard Member

Similar to Allegro Ophthalmics

Vitreoretinal TechnologiesVitreoretinal TechnologiesIrvine, CA, USDrugs, Pharmaceuticalsest. 1999Vitreoretinal TechnologiesIrvine, CA, US · est. 1999

VitreoRetinal Technologies: A biopharmaceutical firm specializing in ophthalmic drugs and diabetic retinopathy treatment.

Series A · $12M6
Alimera SciencesAlimera SciencesAlpharetta, GA, USPharmaceuticalsest. 2003Alimera SciencesAlpharetta, GA, US · est. 2003

Alimera Sciences Inc.: A biopharmaceutical company specializing in ophthalmic pharmaceuticals.

Public · $304.4M145
EyeCyteEyeCyteLos Angeles, CA, USTherapeuticsest. 2005EyeCyteLos Angeles, CA, US · est. 2005

EyeCyte: Developing novel therapeutics for neovascular and degenerative retinal diseases.

Series A · $3M5
Ocular TherapeutixOcular TherapeutixBedford, MA, USOphthalmic Therapiesest. 2006Ocular TherapeutixBedford, MA, US · est. 2006

Ocular Therapeutix, Inc.: Global biopharma innovator in hydrogel-based ophthalmic therapies.

Public · $386.5M274

Vicken Karageozian's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailBrian KimBrian KimCo-Founder · KakaoKim Beom-sooKim Beom-sooCo-Founder · Kakao

People Similar to Vicken Karageozian

Anthony SampietroAnthony SampietroCo-Founder · Ocular ScienceHema RamkumarHema RamkumarCo-Founder · OculogenexRick EiswirthRick EiswirthBoard Member · Alimera SciencesVineet NargolwalaVineet NargolwalaCEO · Allegro MicroSystems